- Home
- CCCC vs MIST Comparison
CCCC vs MIST Comparison
Compare CCCC & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- MIST
- Stock Information
- Founded
- CCCC 2015
- MIST 2003
- Country
- CCCC United States
- MIST Canada
- Employees
- CCCC N/A
- MIST N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- CCCC Health Care
- MIST Health Care
- Exchange
- CCCC Nasdaq
- MIST Nasdaq
- Market Cap
- CCCC 160.1M
- MIST 164.9M
- IPO Year
- CCCC 2020
- MIST N/A
- Fundamental
- Price
- CCCC $2.46
- MIST $2.03
- Analyst Decision
- CCCC Strong Buy
- MIST Strong Buy
- Analyst Count
- CCCC 4
- MIST 3
- Target Price
- CCCC $8.50
- MIST $6.33
- AVG Volume (30 Days)
- CCCC 2.9M
- MIST 1.3M
- Earning Date
- CCCC 11-03-2025
- MIST 11-11-2025
- Dividend Yield
- CCCC N/A
- MIST N/A
- EPS Growth
- CCCC N/A
- MIST N/A
- EPS
- CCCC N/A
- MIST N/A
- Revenue
- CCCC $34,240,000.00
- MIST N/A
- Revenue This Year
- CCCC N/A
- MIST N/A
- Revenue Next Year
- CCCC N/A
- MIST N/A
- P/E Ratio
- CCCC N/A
- MIST N/A
- Revenue Growth
- CCCC 16.55
- MIST N/A
- 52 Week Low
- CCCC $1.09
- MIST $0.63
- 52 Week High
- CCCC $6.52
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- CCCC 51.01
- MIST 54.27
- Support Level
- CCCC $2.31
- MIST $1.92
- Resistance Level
- CCCC $2.82
- MIST $2.14
- Average True Range (ATR)
- CCCC 0.22
- MIST 0.12
- MACD
- CCCC 0.03
- MIST -0.02
- Stochastic Oscillator
- CCCC 52.41
- MIST 30.67
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).